St Jude: CE mark for Genesis migraine therapy the "starting point" of new neurostim opportunity
This article was originally published in Clinica
Executive Summary
St Jude Medical is confident that its Genesis peripheral nerve stimulation (PNS) therapy, which is now CE marked for treating chronic migraine, will play a significant role in driving the company's future growth. This is in spite of uncertainty among market spectators as to whether the use of neurostimulation devices for treating conditions outside its established indications, such as chronic back pain, will really take off.